Exozymes FY26 Q2 net loss widens 22% to $2.88 million; revenue remains no revenue
EXOZ•Higher research spending
Research and development costs jumped 85.7% to USD 2.56 million, due to higher compensation and lab expenses plus reduced grant funding.
Second-quarter and six-month results
Exozymes posted a net loss of USD 5.25 million for the six months ended June 30, 2026, widening 24.5% year over year.
Operating loss widened 18.7% to USD 5.34 million, as operating costs rose 18.7% to USD 5.34 million.
Cash position and going-concern warning
Cash and cash equivalents climbed 86% to USD 5.65 million following June 2026 offerings with net proceeds of USD 5.86 million.
Management flagged substantial doubt about going concern, citing working capital of USD 4.55 million as insufficient for 12 months.
